Vaccinia virus extracellular enveloped virion neutralization in vitro and protection in vivo depend on complement - Test2 - elhamkhani - TriplyDB

Vaccinia virus extracellular enveloped virion neutralization in vitro and protection in vivo depend on complement

Vaccinia virus extracellular enveloped virion neutralization in vitro and protection in vivo depend on complement

http://www.wikidata.org/entity/Q37051617

about

Cloak and Dagger: Alternative Immune Evasion and Modulation Strategies of Poxviruses Complement modulates pathogenesis and antibody-dependent neutralization of West Nile virus infection through a C5-independent mechanism Complement Protein C1q Reduces the Stoichiometric Threshold for Antibody-Mediated Neutralization of West Nile Virus Structural and Biochemical Characterization of the Vaccinia Virus Envelope Protein D8 and Its Recognition by the Antibody LA5 Safety and Immunogenicity of Modified Vaccinia Ankara-Bavarian Nordic Smallpox Vaccine in Vaccinia-Naive and Experienced Human Immunodeficiency Virus-Infected Individuals: An Open-Label, Controlled Clinical Phase II Trial.The mature virion of ectromelia virus, a pathogenic poxvirus, is capable of intrahepatic spread and can serve as a target for delayed therapy.Antibody inhibition of a viral type 1 interferon decoy receptor cures a viral disease by restoring interferon signaling in the liver.A randomized, double-blind, dose-finding Phase II study to evaluate immunogenicity and safety of the third generation smallpox vaccine candidate IMVAMUNE.Protection against lethal vaccinia virus challenge by using an attenuated matrix protein mutant vesicular stomatitis virus vaccine vector expressing poxvirus antigens.A recombinant flagellin-poxvirus fusion protein vaccine elicits complement-dependent protection against respiratory challenge with vaccinia virus in mice Antibody against extracellular vaccinia virus (EV) protects mice through complement and Fc receptors.Combination therapy of vaccinia virus infection with human anti-H3 and anti-B5 monoclonal antibodies in a small animal model.Smallpox inhibitor of complement enzymes (SPICE): dissecting functional sites and abrogating activity Ectromelia virus inhibitor of complement enzymes protects intracellular mature virus and infected cells from mouse complement.A protein-based smallpox vaccine protects non-human primates from a lethal monkeypox virus challenge.Poxvirus complement control proteins are expressed on the cell surface through an intermolecular disulfide bridge with the viral A56 protein.Elucidating the role of the complement control protein in monkeypox pathogenicity Epitope mapping by random peptide phage display reveals essential residues for vaccinia extracellular enveloped virion spread.Therapeutic Vaccines and Antibodies for Treatment of Orthopoxvirus Infections.Protection of rabbits and immunodeficient mice against lethal poxvirus infections by human monoclonal antibodies.Postexposure prevention of progressive vaccinia in SCID mice treated with vaccinia immune globulin Capturing the natural diversity of the human antibody response against vaccinia virus The Vaccinia virus complement control protein modulates adaptive immune responses during infection Antigen experience shapes phenotype and function of memory Th1 cells Smallpox vaccines: targets of protective immunity.An epitope conserved in orthopoxvirus A13 envelope protein is the target of neutralizing and protective antibodies Passive immunotherapies protect WRvFire and IHD-J-Luc vaccinia virus-infected mice from lethality by reducing viral loads in the upper respiratory tract and internal organs T cell antigen discovery using soluble vaccinia proteome reveals recognition of antigens with both virion and nonvirion association.Parainfluenza virus 5-based vaccine vectors expressing vaccinia virus (VACV) antigens provide long-term protection in mice from lethal intranasal VACV challenge.Vaccinia extracellular virions enter cells by macropinocytosis and acid-activated membrane rupture.Polyclonal antibody cocktails generated using DNA vaccine technology protect in murine models of orthopoxvirus disease.Disabling complement regulatory activities of vaccinia virus complement control protein reduces vaccinia virus pathogenicity.Poorly neutralizing cross-reactive antibodies against the fusion loop of West Nile virus envelope protein protect in vivo via Fcgamma receptor and complement-dependent effector mechanisms.Cowpox virus induces interleukin-10 both in vitro and in vivo Measurement of antibody responses to Modified Vaccinia virus Ankara (MVA) and Dryvax(®) using proteome microarrays and development of recombinant protein ELISAs Susceptibility of Marmosets (Callithrix jacchus) to Monkeypox Virus: A Low Dose Prospective Model for Monkeypox and Smallpox Disease.Structural and Functional Characterization of Anti-A33 Antibodies Reveal a Potent Cross-Species Orthopoxviruses Neutralizer.Serological responses in humans to the smallpox vaccine LC16m8.Adsorption of recombinant poxvirus L1-protein to aluminum hydroxide/CpG vaccine adjuvants enhances immune responses and protection of mice from vaccinia virus challenge Unusual features of vaccinia virus extracellular virion form neutralization resistance revealed in human antibody responses to the smallpox vaccine.

P2860

Q26797325-3EC27538-B71A-4F06-9127-1FFB0901165F Q27489809-5224D5AD-E2A4-4CF5-AEA6-CD80FAEE9CEE Q27490423-1EC5BF40-5DC9-406F-9C31-265FD247A4F9 Q27679281-7FA99DBF-9990-477F-82B2-1F15B8A00AED Q30151079-8E846F3D-35E5-442A-B30A-6DFFC2E88E3D Q30223108-9867ADE5-186C-4694-9D1F-31317A8D2B3E Q31045190-5A2800F1-0795-43FA-B15C-02879C0490BA Q33624420-4208AA44-0834-45BD-A6EA-38933D2E5CE8 Q33725635-2A7F1CDB-CE11-4513-A1FA-D02EAC2781AE Q33905188-DB336342-0799-44F6-B684-5AE7665A53BA Q33936717-95A20EE0-33EA-4A11-BAC4-F52F2EDA7D7F Q33967713-CAAB9C2A-182E-47BA-A653-00D05E4C38AA Q33972574-A24C144C-062D-493F-8A49-B34326CA6330 Q34120177-65EC1249-0465-4172-B823-5BCAAEE4579E Q34126697-F708727C-04E2-4158-BE68-BEBFDFCD8C67 Q34190609-D334226C-1003-45E9-A9EC-C35495CDA9B8 Q34230482-DC0CB584-0A61-46C5-9D32-AB7D2B86AF86 Q34420319-FFE727BA-0A84-48AB-A3F6-07B38060F177 Q34447009-81BE6CF5-D1E0-420C-9523-E66FAF8AF7B6 Q34469836-308BEB8E-FA4F-41DF-8D94-CDA521CFB611 Q34484027-3A860F8C-A845-45DC-8340-D1FEA2304503 Q34529713-BC808DCF-A7D1-4B78-B01E-49B3319E3313 Q34742926-E13BAB4E-1585-44EB-A484-D62CFA25EDD9 Q34769714-6678465C-1F3C-4B4C-83F4-EB4D9FA696D2 Q34780607-A0117186-CB34-4B7D-9274-C39C5C860300 Q35186318-FFABCC3E-C064-423F-8D5E-4170A96391A0 Q35192889-AD8C31A7-E454-4336-A6B1-AA2149C3E52F Q35206861-75260E25-56C3-43C1-8C9A-F3D0A8DE4F13 Q35226200-B0D5D6E6-CFC1-493E-8FD3-0844EDD6A3B5 Q35236032-43F8576C-3801-4C0E-8B5E-A0F7E57A7E38 Q35339702-C9FB1DFA-0FB8-4BE2-923A-DB611A3D831B Q35367093-51FDEF1B-D0DC-4D49-B80D-0AA2EF4F79D6 Q35531167-8A6B05B1-D161-44B4-BEA9-05A30010F3AC Q35539329-6A794B97-C20A-4BEC-AA00-00F05CB499EE Q35634159-8223BADB-9D72-4BE4-9926-6EA9AC78BA29 Q35683735-BC5E4F13-D346-48D4-A59B-30941A469DCF Q35760869-02F0DA8B-C0AA-4F0D-AFEB-45FEF98F6E2E Q35945094-CA1D9D34-49EB-43FA-B2AA-09A90A011206 Q36487366-9B17B448-5284-48C6-BBEE-5807B3750D17 Q36559797-C8A2040C-2D49-4E35-B44F-574345B6B8D0

P2860

Vaccinia virus extracellular enveloped virion neutralization in vitro and protection in vivo depend on complement

http://www.wikidata.org/entity/Q37051617

description

2008 nî lūn-bûn

@nan

2008年の論文

@ja

2008年学术文章

@wuu

2008年学术文章

@zh-cn

2008年学术文章

@zh-hans

2008年学术文章

@zh-my

2008年学术文章

@zh-sg

2008年學術文章

@yue

2008年學術文章

@zh

2008年學術文章

@zh-hant

name

Vaccinia virus extracellular e ...... n in vivo depend on complement

@en

Vaccinia virus extracellular e ...... in vivo depend on complement.

@nl

type

label

Vaccinia virus extracellular e ...... n in vivo depend on complement

@en

Vaccinia virus extracellular e ...... in vivo depend on complement.

@nl

prefLabel

Vaccinia virus extracellular e ...... n in vivo depend on complement

@en

Vaccinia virus extracellular e ...... in vivo depend on complement.

@nl

P1433

Q37051617-347AF43F-A040-48D5-B3AA-7BE07D5A716F

P1476

Q37051617-62BE76EA-E443-41F3-8BFB-687BB6147A66

P2093

Q37051617-0DA5432A-3BD6-4BCF-94A7-2D83008406F6

Q37051617-17BBB8AC-5825-4DAB-9FCD-C866F6F1150D

Q37051617-18244230-04A2-447E-8BBC-2CEC7ED0D638

Q37051617-1995CEAD-29FB-4AB8-965F-8B9C71B7CC0E

Q37051617-44700A77-F44E-4665-B996-9940C7927FDB

Q37051617-54CAF067-822F-4638-9FB0-85DC5E95DB3D

Q37051617-55880EC6-6710-442A-AF40-61BE6634E54A

Q37051617-754E7604-26AC-42A4-9CFD-13083A6BA5BB

Q37051617-9B3EF93C-9199-45FD-8236-24623758ED76

Q37051617-D43F433E-23E1-493D-89AD-7D56668FA789

P2860

Q37051617-03984E5D-07F4-40CC-BF4C-15B3AF79C4FF

Q37051617-08CE74EE-BA17-4C6E-9301-08FC54598198

Q37051617-09EB1DB6-1329-4BC1-A59B-00E065BF9CC6

Q37051617-11B1A191-4941-4002-8782-7404112EDB3E

Q37051617-135FD2A6-2813-4096-B0DB-65A6644ADBDA

Q37051617-1440FB1C-8DFE-4873-9128-CD82193EA317

Q37051617-165D3FD2-8547-4D38-BAA5-46F24BD76036

Q37051617-1D041365-8708-4E47-85FF-107486B379A9

Q37051617-1FDE50D8-49BF-4247-B716-B5B69832C6B9

Q37051617-202160E8-597B-4CC3-BC3E-FA8E2BC9E403

P304

Q37051617-33A882D0-9943-40C2-9B01-620773A4A800

P31

Q37051617-7A964244-55E6-4FF0-BEE7-3C9E8802EEDE

P356

Q37051617-F9CDE27C-FB62-47C1-B5CD-F4BF4F79039D

P407

Q37051617-5F862B0A-AAD8-4029-98FC-653EAB658BB8

P433

Q37051617-1B6AD6DE-6F54-465A-81D4-7BF935EAF14E

P478

Q37051617-D379AB50-BDAA-412A-BFE7-FB8475C33E25

P577

Q37051617-E225B57D-B3B4-4C88-91F0-24858ECC3EA0

P698

Q37051617-34861249-CA0A-4BC1-91A5-CF4A0F409126

P932

Q37051617-DBE2EAA2-2E88-4A6A-AADE-62E425D3EE17

P356

P1433

Journal of Virology

P1476

Vaccinia virus extracellular e ...... n in vivo depend on complement

@en

P2093

John Laudenslager

http://www.w3.org/2001/XMLSchema#string

Juan Moyron

http://www.w3.org/2001/XMLSchema#string

Lilia Koriazova

http://www.w3.org/2001/XMLSchema#string

Megan M McCausland

http://www.w3.org/2001/XMLSchema#string

Mohammed Rafii-El-Idrissi Benhnia

http://www.w3.org/2001/XMLSchema#string

Ralph Kubo

http://www.w3.org/2001/XMLSchema#string

Sandra Rickert

http://www.w3.org/2001/XMLSchema#string

Shane Crotty

http://www.w3.org/2001/XMLSchema#string

Shinichiro Kato

http://www.w3.org/2001/XMLSchema#string

Steven Granger

http://www.w3.org/2001/XMLSchema#string

P2860

Smallpox DNA vaccine protects nonhuman primates against lethal monkeypox

Complement activation is required for induction of a protective antibody response against West Nile virus infection

Protective immune responses against West Nile virus are primed by distinct complement activation pathways

Complement Protein C1q Inhibits Antibody-Dependent Enhancement of Flavivirus Infection in an IgG Subclass-Specific Manner

The Stoichiometry of Antibody-Mediated Neutralization and Enhancement of West Nile Virus Infection

Vaccinia virus encodes a secretory polypeptide structurally related to complement control proteins

Intravenous immunoglobulin products contain neutralizing antibodies to vaccinia.

A protein-based smallpox vaccine protects mice from vaccinia and ectromelia virus challenges when given as a prime and single boost.

Visualization of intracellular movement of vaccinia virus virions containing a green fluorescent protein-B5R membrane protein chimera.

Profiling the humoral immune response to infection by using proteome microarrays: high-throughput vaccine and diagnostic antigen discovery

P304

1201-1215

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1128/JVI.01797-08

http://www.w3.org/2001/XMLSchema#string

P407

P433

3

http://www.w3.org/2001/XMLSchema#string

P478

83

http://www.w3.org/2001/XMLSchema#string

P577

2008-11-19T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

19019965

http://www.w3.org/2001/XMLSchema#string

P932

2620895

http://www.w3.org/2001/XMLSchema#string